semaglutide after breast cancer GLP-1 Receptor Agonists in Cancer: A New Frontier in Obesity and Prognosis Management Frontiers | GLP-1 receptor agonist

Increased odds of pregnancy by 1.34 (12 RCTs, 1246 women, moderate quality evidence) No difference in miscarriage rates (8 RCTs, 950 women, moderate quality evidence) Length of treatment varied from 2 to 26 weeks no conclusion on optimal length Dosage varied but most common was 75 mg/day Additionally, this Cochrane review identified two studies with women who were not PORs and found no difference in pregnancy rates

Research indicates that without a plan to protect muscle, up to forty per cent of weight lost during GLP-1 therapy may come from lean body mass

IV bioavailability is assumed near 100% and serves as the reference

Genetically predicted acetyl-carnitine and cardiovascular disease by sex

However, some benefits, like skin whitening or improved detoxification, may gradually diminish